Table 6.
Summary of recent clinical trials using MSCs for Parkinson’s disease.
| Reference | Disease | Source | Number | Mean Age (Range), Year | Route of Administration | Number of Cells | Number of Treatments | Results | Adverse Events | |
|---|---|---|---|---|---|---|---|---|---|---|
| Trial | Control | |||||||||
| Canesi et al. [89] | Progressive supranuclear palsy (Phase 1) |
BM | 5 | 0 | 60–68 | IA (intra-arterial) via catheterization | 1.7 (1.2–2.0) × 106/kg | 1 | Clinical stabilization for at least 6 months during the one-year follow-up | Transient left hemiparesis |
| Carstens et al. [90] | Parkinson’s disease (Case studies) |
AD MSC-derived stromal vascular fraction | 2 | 0 | 72, 50 | Facial and nasal transplantation | 6.0 × 107 cells | 1 | Subjective functional recovery after 2 weeks and up to 5 years | No |
BM, bone marrow; AD, adipose.